Katarzyna Zachwieja

Katarzyna Zachwieja


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AWAleksandra Wieczorek
Aleksandra Wieczorek
CMCarla Manzitti
Carla Manzitti
AGAlberto Garaventa
Alberto Garaventa
JGJuliet Gray
Juliet Gray
VPVassilios Papadakis
Vassilios Papadakis
Holger N. LodeHolger N. Lode
Holger N. Lode
Neurotoxicity is an off-tumour, on-target side effect of GD2-directed immunotherapy with monoclonal antibodies. Here, we report the frequency, management and outcome of patients enrolled in two prospective clinical trials who experienced severe neurotoxicity during immunotherapy with the anti-GD2 antibody dinutuximab beta (DB) administered as short-term infusion (HR-NBL1/SIOPEN study, randomisation R2, EudraCT 2006-001489-17) or as long-term infusion (HR-NBL1/SIOPEN study, randomisation R4, EudraCT 2006-001489-17 and LTI/SIOPEN study, EudraCT 2009-018077-31), either alone or with subcutaneous interleukin-2 (scIL-2). The total number of patients included in this analysis was 1102. Overall, 44/1102 patients (4.0%) experienced Grade 3/4 neurotoxicities (HR-NBL1 R2, 21/406; HR-NBL1 R4, 8/408; LTI study, 15/288), including 27 patients with severe neurotoxicities (2.5%). Events occurred predominantly in patients receiving combined treatment with DB and scIL-2. Neurotoxicity was treated using dexamethasone, prednisolone, intravenous immunoglobulins and, in two patients, plasmapheresis, which was highly effective. While neurological recovery was observed in 16 of 21 patients with severe neurotoxicities, 5/1102 (0.45%) patients experienced persistent and severe neurological deficits. In conclusion, severe neurotoxicity is most commonly observed in patients receiving DB with scIL-2. Considering the lack of clinical benefit for IL-2 in clinical trials so far, the administration of IL-2 alongside DB is not recommended.

1 March 2015 in Advances in Medical Sciences
Verified
Journal Article
Closed access
KZKatarzyna Zachwieja
Katarzyna Zachwieja
PKPrzemysław Korohoda
Przemysław Korohoda
JKJoanna Kwinta-Rybicka
Joanna Kwinta-Rybicka
MMMonika Miklaszewska
Monika Miklaszewska
AMAnna Moczulska
Anna Moczulska
JPJacek Pietrzyk
Jacek Pietrzyk

20 September 2021 in Genes
Verified
Journal Article
Open access
PDF file
LSLuca Schierbaum
Luca Schierbaum
SSSophia Schneider
Sophia Schneider
SHStefan Herms
Stefan Herms
SSSugirthan Sivalingam
Sugirthan Sivalingam
JFJulia Fabian
Julia Fabian
AHAlina Christine Hilger
Alina Christine Hilger
Lower urinary tract obstruction (LUTO) is, in most cases, caused by anatomical blockage of the bladder outlet. The most common form are posterior urethral valves (PUVs), a male-limited phenotype. Here, we surveyed the genome of 155 LUTO patients to identify disease-causing CNVs. Raw intensity data were collected for CNVs detected in LUTO patients and 4.392 healthy controls using CNVPartition, QuantiSNP and PennCNV. Overlapping CNVs between patients and controls were discarded. Additional filtering implicated CNV frequency in the database of genomic variants, gene content and final visual inspection detecting 37 ultra-rare CNVs. After, prioritization qPCR analysis confirmed 3 microduplications, all detected in PUV patients. One microduplication (5q23.2) occurred de novo in the two remaining microduplications found on chromosome 1p36.21 and 10q23.31. Parental DNA was not available for segregation analysis. All three duplications comprised 11 coding genes: four human specific lncRNA and one microRNA. Three coding genes (FBLIM1, SLC16A12, SNCAIP) and the microRNA MIR107 have previously been shown to be expressed in the developing urinary tract of mouse embryos. We propose that duplications, rare or de novo, contribute to PUV formation, a male-limited phenotype.

6 July 2013
Verified
Journal Article
Closed access
MMMonika Miklaszewska
Monika Miklaszewska
PKPrzemysław Korohoda
Przemysław Korohoda
KZKatarzyna Zachwieja
Katarzyna Zachwieja
TMTomasz Mroczek
Tomasz Mroczek
DDDorota Drożdż
Dorota Drożdż
JPJacek Pietrzyk
Jacek Pietrzyk

22 March 2016 in Renal Failure
Verified
Journal Article
Open access
PDF file
KZKatarzyna Zachwieja
Katarzyna Zachwieja
PKPrzemysław Korohoda
Przemysław Korohoda
JKJoanna Kwinta-Rybicka
Joanna Kwinta-Rybicka
MMMonika Miklaszewska
Monika Miklaszewska
AMAnna Moczulska
Anna Moczulska
JPJacek Pietrzyk
Jacek Pietrzyk
Aim: Estimation of eGFR in children with normal kidney function using the Schwartz equations results in underestimating real GFR. Materials and methods: We propose modification of three Schwartz equations – two based on creatinine concentration (eGFRScrBS bedside) and (eGFRScr) and one 3-marker based on creatinine, urea and cystatin C concentrations (eGFRS3M). The iohexol test (reference method) was performed 417 times in 353 children >2 years with mean GFR: 98 ± 31.6 ml/min/1.73m2. The assessment included also the Filler and Zappitelli equations. The modification was performed using methods: (1) based on equation, eGFRcor = a [eGFR − T] + T, where T = 50, if eGFR > T, and a equals for: eGFRScrBS 1.4043, for eGFRScr 2.0048, for eGFRS3M 1.2951, and (2) based on correction of all coefficients of the original equation. Results: For comparison of all the results and for children with GFR< 60, 60-90, 90-135 and > 135 ml/min/1.73m2 the correlation coefficient, relative error (RE) and root mean square relative error (RMSRE) was employed and revealed improvement of RE from 25.9 to 6.8 and 3.9% (depending on the correction method) for eGFRScr; from 19 to 8.1 and 3.9% for eGFRScrBS and: from 11.6% to 2.0 and 2.3% for eGFRS3M (respectively). The RMSRE values changed from 30 to 21.3 and 19.8% for eGFRScr, from 25.1 to 21.6 and 19.8% for eGFRScrBS and from 19.1 to 15.8 and 15.3 % for eGFRS3M. Conclusions: Modifications of Schwartz equations at GFR > 60 ml/min/1.73m2 significantly improves the accuracy of calculating eGFR. The 3-markers equation is more accurate and should be employed frequently.

MMMonika Miklaszewska
Monika Miklaszewska
PKPrzemysław Korohoda
Przemysław Korohoda
KZKatarzyna Zachwieja
Katarzyna Zachwieja
MWMichał Wolnicki
Michał Wolnicki
MMMałgorzata Mizerska-Wasiak
Małgorzata Mizerska-Wasiak
JPJacek Pietrzyk
Jacek Pietrzyk
Myelomeningocele (MMC) results from a failure of normal neural tube fusion in early fetal development. Retrospective, observational study of medical data of 54 children treated in Pediatric Nephrology and Urology Clinics for five years was performed. The following data were analyzed: serum creatinine, eGFR, urine analysis, renal scintigraphy (RS), renal ultrasound, and urodynamics. Mean age of studied population: 12.3 years, median of eGFR at the beginning and at the end of survey was 110.25 and 116.5 mL/min/1.73 m2 accordingly. Median of frequency of urinary tract infections (fUTI): 1.2 episodes/year. In 24 children: low-pressure, in 30 children: high-pressure bladder was noted. Vesicouretral reflux (VUR) was noted in 23 children (42.6%). fUTI were more common in high-grade VUR group. High-grade VURs were more common in group of patients with severe renal damage. At the end of the survey 11.1% children were qualified to higher stages of chronic kidney disease. Renal parenchyma damage progression in RS was noted in 22.2% children. Positive VUR history, febrile recurrent UTIs, bladder wall trabeculation, and older age of the patients constitute risk factors of abnormal renal scans. More than 2.0 febrile, symptomatic UTIs annually increase by 5.6-fold the risk of severe renal parenchyma damage after five years.